Moderna Inc is trading 4.3% down at $49.37 as the stock consolidates gains following a significant multi-day surge driven by positive clinical data.
- The recent rally was fueled by highly positive 5-year cancer vaccine data presented in collaboration with Merck at the ASCO 2026 conference.
- Shares are facing pressure amid a broader risk-off move in U.S. equities following a hotter-than-expected jobs report and shifting Fed rate expectations.
- Growth and technology names are under pressure as investors recalibrate the outlook for interest rates and economic policy.